Bust­ed in the wake of a CRL, Athenex brings out bud­get axe af­ter 'go­ing con­cern' alert

Last year
Deals

Apel­lis ris­es on long-term da­ta for Soliris chal­lenger af­ter mixed PhI­II read­out, and an­a­lysts are more bull­ish on ap­proval

Last year
R&D

A lit­tle biotech crows about its Covid-19 'one and done' PhI­II, caus­ing at least one top an­a­lyst to change his tune as shares soar

Last year
R&D
Coronavirus

Al­ny­lam seeks com­pen­sa­tion from Mod­er­na and Pfiz­er in suits over patent­ed de­liv­ery of their Covid-19 vac­cines

Last year
Coronavirus
Law

Bio­gen los­es an­oth­er bid to re­vive Tec­fidera patent as gener­ic keeps eat­ing in­to block­buster sales

Last year
Pharma
Law

As­traZeneca shells out $775M to set­tle Ul­tomiris patent suit with Roche

Last year
Pharma
Law

J&J's Alex Gorsky bagged $26M in pay and perks for 2021, land­ing near the top of the Big Phar­ma CEO lad­der

Last year
People
Pharma

Pub­li­cis brings back its Health­Front deal­mak­ing mar­ket­place for phar­ma and health­care ad­ver­tis­ers

Last year
Pharma
Marketing

Phar­ma in­dus­try rep­u­ta­tion con­tin­ues to slide, ac­cord­ing to new Har­ris Poll. But how low can it go?

Last year
Pharma
Marketing

Sanofi part­ners up with dom­i­nant ADC play­er Seagen, dou­bling down on on­col­o­gy in hunt for a bet­ter pipeline

Last year
Deals
R&D

With its share price chewed to pieces, Nick Leschly's 2sev­en­ty scores $170M to help weath­er the storm

Last year
Financing
Bioregnum

Bio­gen fi­nal­ly pub­lish­es PhI­II re­sults for Aduhelm as crit­ics chas­tise low-rank­ing jour­nal, ‘gen­tle and un­re­veal­ing’ peer re­view

Last year
Pharma

With new RSV an­ti­body, Sanofi looks to avoid a re­peat of a 20-year-old pric­ing con­tro­ver­sy

Last year
R&D
Pharma

Back to the fun­da­men­tals: Fra­zier rolls out $1B fund to ramp up a new slate of biotech star­tups

Last year
Financing

Biotech founders sen­tenced to 1 year and 1 day for steal­ing Genen­tech se­crets, ly­ing to in­vestors

Last year
People
Law

Mar­ket­ingRx roundup: Pfiz­er’s CEO talks pan­dem­ic pres­sure at SXSW; Ex­act Sci­ences teams with Katie Couric for screen­ing

Last year
Pharma
Marketing

Pushed out of Eli Lil­ly in ethics scan­dal, Josh Smi­ley lands a top job at Zai Lab

Last year
People

Mer­ck suf­fers rare Keytru­da set­back as the block­buster fails a PhI­II prostate can­cer test with Lyn­parza

Last year
R&D

No­vo Nordisk, Gates Foun­da­tion pledge $90M to fund an­tivi­ral re­search for the next pan­dem­ic

Last year
R&D
Discovery

Root­ing for a come-from-be­hind win, Black­stone in­fus­es $330M in­to Sanofi's CD38 de­vel­op­ment plan

Last year
R&D

Ei­sai finds an ex­it from Aduhelm, with small roy­al­ties if it ever nabs cov­er­age

Last year
Pharma

FDA or­ders In­cyte to hold up yet again in the hunt for block­buster fran­chise

Last year
FDA+

Nek­tar crushed — again — as Bris­tol My­ers al­ly runs in­to PhI­II melanoma fail

Last year
R&D

FDA hits back Fasen­ra in key rhi­nos­i­nusi­tis field, putting As­traZeneca even fur­ther be­hind Big Phar­ma ri­vals

Last year
Pharma
FDA+
First page Previous page 109110111112113114115 Next page Last page
A service from the Financial Times